

SEP. 3 (WED) – 5 (FRI) | GRAND WALKERHILL SEOUL, KOREA

• Name:	Jeong Il Yu			
• Current Position & Affiliation:	Associate Professor, Department of Radiation			
	Oncology,	Samsung	Medical	Center,
	Sungkyunkw	an University	School of N	Medicine,
	Seoul, Korea	L		
• Country:	Korea			

## • Educational Background:

1999~2005	MD at CHA University, College of Medicine
	(former School of Medicine, Pocheon Cha University)
2008~2012	Master's course and a degree
	The graduate school, Chungbuk National University, Chongju-si, Korea
2012~2017	Ph.D.'s course and a degree
	The graduate school, Sungkyunkwan University School of Medicine, Seoul, Korea

## • Professional Experience:

2013~2015	Clinical fellow, Department of Radiation Oncology, Samsung Medical Center, Seoul
2015~2016	Instructor, Department of Radiation Oncology, Samsung Medical Center, Seoul
2016~2018	Clinical Assistant Professor, Department of Radiation Oncology,
	Samsung Medical Center, Seoul
2019~2023	Assistant Professor, Department of Radiation Oncology,
	Sungkyunkwan University School of Medicine Samsung Medical Center, Seoul
2023~	Associate Professor, Department of Radiation Oncology,
	Sungkyunkwan University School of Medicine Samsung Medical Center, Seoul

## • Professional Organizations:

2005.3: Member, Korean Medical Association (KMA)
2010.3: Member, Korean Society for Radiation Oncology (KOSRO)
2013.5: Member, Korean Cancer Association (KCA)
2013.5: Member, Korean Society of Medical Oncology (KSMO)

SEP. 3 (WED) – 5 (FRI) | GRAND WALKERHILL SEOUL, KOREA

**KSVO** 2025

2013.5: Member, The Korean Liver Cancer Association (KLCA)

## • Main Scientific Publications:

1. Min JH, Yu JI, Kim SH, Kim YK, Kim K, Park HC, et al. Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer. J Cachexia Sarcopenia Muscle. 2025;16(1):e16343.

2. Moon JY, Park JB, Lee KW, Park D, Yoo GS, Choi C, et al. Identification and validation of soft tissue sarcoma-specific transcriptomic model for predicting radioresistance. Int J Radiat Biol. 2025;101(3):283-91.

3. Yu JI, Park HC, Shin H, Park H, Shin SW, Cho SK, et al. External validation of subclassification system and progression pattern analysis in hepatocelluar carcinoma with macroscopic vascular invasion. Radiother Oncol. 2023;187:109841

4. Jo SJ, Park SSW, Yoo GS, Kim KD, Lim SH, Kim J, et al. Effect of pre-operative radiation therapy on surgical outcome in retroperitoneal sarcoma. Front Surg. 2023;10:1209698.

5. Yu JI, Yoo GS, Park HC, Choi DH, Lee WY, Yun SH, et al. Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer. Ann Surg Oncol. 2022

6. Kim K, Yu JI, Park HC, Yoo GS, Lim DH, Noh JM, et al. A phase II trial of hypofractionated highdose proton beam therapy for unresectable liver metastases. Radiother Oncol. 2022;176:9-16.

7. Kim N, Yu JI, Park HC, Yoo GS, Choi C, Hong JY, et al. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. Cancer Immunol Immunother. 2021;70(6):1593-603.